Biotech · Public company · Boston, MA, US

Allarity Therapeutics, Inc.

Ticker ALLR · SEC CIK 0001860657

Track this companyFree. Adds Allarity Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials32 recruiting or active

Pipeline programs8From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline8

2X-121Phase 2 · Advanced Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
2X-121 + 300 mg dovitinibPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
2X-121 + 400 mg dovitinibPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
2X-121 + 500 mg dovitinibPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
2X-121 1000 mgPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
2X-121 600 mgPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
2X-121 800 mgPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Drug Response Predictor® (DRP)Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026

Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid TumorsPHASE1 · TERMINATED · started Mar 8, 2023ClinicalTrials.gov NCT05571969 · fetched Nov 12, 2026
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian CancerPHASE2 · RECRUITING · started Apr 15, 2019ClinicalTrials.gov NCT03878849 · fetched Nov 12, 2026
Clinical Pre-screening Protocol for Ovarian CancerRECRUITING · started Apr 11, 2019ClinicalTrials.gov NCT03877796 · fetched Nov 12, 2026